ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive: AXL overexpression and/or activation has been linked with resistance to chemotherapy in gastrointestinal stromal tumor cell lines [14], in CML cells [11], rhabdomyosarcoma [15], HER-2 positive breast tumor cells [16] and ovarian cancer [17].